NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
76.42
-0.57 (-0.74%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close76.99
Open76.24
Bid0.00 x 0
Ask0.00 x 0
Day's Range75.73 - 76.56
52 Week Range75.73 - 94.19
Volume1,294,357
Avg. Volume1,833,059
Market Cap179.032B
Beta0.88
PE Ratio (TTM)23.51
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.98 (3.87%)
Ex-Dividend Date2018-03-06
1y Target EstN/A
Trade prices are not sourced from all markets
  • 5 Biotech ETFs for Outsized Gains
    InvestorPlace13 hours ago

    5 Biotech ETFs for Outsized Gains

    The healthcare sector, the third-largest sector allocation in the S&P 500, is usually viewed as a defensive space, but within the space lie plenty of growth opportunities — and much of the healthcare sector’s growth appeal comes by way of biotechnology stocks.

  • Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release
    Market Realist13 hours ago

    Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release

    In 1Q18, analysts expect Sanofi’s (SNY) revenue to fall ~6.6% YoY (year-over-year) to 8.1 billion euros from 8.7 billion euros, and its earnings per share to fall to 1.13 euros from 1.42 euros. Sanofi’s stock price has fallen ~9.4% over the last 12 months and ~7.1% year-to-date. Analysts’ price target of $47.67 suggests the stock could return ~19.2% over the next 12 months based on its price of $39.95 on April 23.

  • Novartis Delivered Strong Performance in 1Q18
    Market Realist14 hours ago

    Novartis Delivered Strong Performance in 1Q18

    Novartis (NVS) delivered a strong performance in the first quarter of fiscal 2018. Its net sales grew 4% to $12.7 billion, driven by higher product sales of Entresto, Cosentyx, and oncology products. Entresto sales grew to $200 million, driven by higher worldwide uptake. Cosentyx sales grew 35% to $580 million due to expanded access and a strong growth in all indications.

  • GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings
    Market Realist16 hours ago

    GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings

    GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.

  • Novartis Launches FocalView to Modernize Clinical Trials
    Market Realist16 hours ago

    Novartis Launches FocalView to Modernize Clinical Trials

    Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.

  • Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18
    Market Realist16 hours ago

    Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18

    In 1Q18, Amgen (AMGN) generated revenue of $5.6 billion, representing ~2% YoY (year-over-year) growth from its revenue of $5.5 billion in 1Q17. Quarter-over-quarter, its revenue fell ~4%. Amgen’s GAAP (generally accepted accounting principles) operating income and net income rose ~5% and ~12% YoY, respectively, to $2.7 billion and $2.3 billion from $2.6 billion and $2.1 billion.

  • Gilead Sciences has a Strong Oncology Research Program
    Market Realist19 hours ago

    Gilead Sciences has a Strong Oncology Research Program

    Gilead Sciences (GILD) is currently studying a combination of anti-MMP-9 (anti-matrix metalloproteinase-9) antibody andecaliximab with modified FOLFOX 6 in a Phase 3 trial as a therapy for treatment-naïve advanced gastric or GAMMA-1 (gastroesophageal junction adenocarcinoma) patients. The company also expects to conclude its Phase 2 trial comparing an andecaliximab-nivolumab combination with a nivolumab monotherapy in gastric cancer in 2018. If these trials prove successful, Gilead Sciences could emerge as major competition for other gastric cancer therapy players such as Eli Lilly (LLY) and Roche (RHHBY).

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
    Zacks19 hours ago

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay

  • Glaxo (GSK) Misses on both Earnings and Revenue in Q1
    Zacks20 hours ago

    Glaxo (GSK) Misses on both Earnings and Revenue in Q1

    Glaxo's (GSK) Q1 earnings and revenue miss estimates. In the event of introduction of Advair generic in the U.S. market by mid-year, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

  • Novartis' digital drive continues with eye-disease app
    Reutersyesterday

    Novartis' digital drive continues with eye-disease app

    Novartis's foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies. It is using Apple's ResearchKit for its "FocalView" application to help researchers track ophthalmic disease progression by collecting data directly from patients without requiring them to travel to a doctor. As Chief Executive Vas Narasimhan focuses the Basel-based company on innovative medicines via acquisitions like this month's $8.7 billion takeover of U.S.-based AveXis, he is also plowing resources into digital technology in a bid to boost trial success, save time and cut costs.

  • Novartis' digital drive continues with eye-disease app
    Reutersyesterday

    Novartis' digital drive continues with eye-disease app

    Novartis's foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies. It is using Apple's ResearchKit for its "FocalView" application to help researchers track ophthalmic disease progression by collecting data directly from patients without requiring them to travel to a doctor. As Chief Executive Vas Narasimhan focuses the Basel-based company on innovative medicines via acquisitions like this month's $8.7 billion takeover of U.S.-based AveXis, he is also plowing resources into digital technology in a bid to boost trial success, save time and cut costs.

  • Reutersyesterday

    Novartis' digital drive continues with eye-disease app

    Novartis's foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies. It is using Apple's ResearchKit for its "FocalView" application to help researchers track ophthalmic disease progression by collecting data directly from patients without requiring them to travel to a doctor. As Chief Executive Vas Narasimhan focuses the Basel-based company on innovative medicines via acquisitions like this month's $8.7 billion takeover of U.S.-based AveXis, he is also plowing resources into digital technology in a bid to boost trial success, save time and cut costs.

  • The Wall Street Journalyesterday

    [$$] How Long Till the Final World Malaria Day?

    Wiping the disease out by 2040 could save 11 million lives.

  • Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley
    Zacksyesterday

    Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley

    Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley

  • Forbes2 days ago

    Is Biopharma Investing Too Much In Cancer R&D?

    Jay Bradner is the president of Novartis’ Institutes for BioMedical Research, the organization entrusted with Novartis’ R&D budget of $9 billion -- one of the largest in the industry. Furthermore, Novartis is a leading innovator in the oncology field with targeted therapies as well as the recently launched CAR-T therapy Kymriah for a deadly childhood leukemia. This is a time of extraordinary promise for cancer medicine, with unambiguous evidence of progress in the innovation of both targeted and immune-oncology therapies.

  • Shire (SHPG) Turns Down Takeda's Third Buyout Proposition
    Zacks6 days ago

    Shire (SHPG) Turns Down Takeda's Third Buyout Proposition

    Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.

  • What's in the Cards for Glaxo (GSK) This Earnings Season?
    Zacks6 days ago

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

  • Novartis (NVS) Reports Encouraging Data on MS Candidate
    Zacks6 days ago

    Novartis (NVS) Reports Encouraging Data on MS Candidate

    Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks6 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
    Zacks6 days ago

    J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

    Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

  • Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint
    Investor's Business Daily6 days ago

    Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint

    Novartis beat earnings and revenue forecasts, but generics revenue tumbled and a key drug missed sales estimates.

  • Novartis AG (ADR) Stock Drops on Q1 Earnings Miss
    InvestorPlace7 days ago

    Novartis AG (ADR) Stock Drops on Q1 Earnings Miss

    Novartis AG (ADR) (NYSE:NVS) stock took a hit on Thursday following the release of its earnings report for the first quarter of 2018.Source: Shutterstock

  • Novartis AG (NVS) Q1 2018 Earnings Conference Call Transcript
    Motley Fool7 days ago

    Novartis AG (NVS) Q1 2018 Earnings Conference Call Transcript

    NVS earnings call for the period ending March 31, 2018.

  • Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
    Zacks7 days ago

    Novartis (NVS) Beats Earnings and Revenue Estimates in Q1

    Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks7 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.